United States

People: ZIOPHARM Oncology Inc (ZIOP.OQ)

ZIOP.OQ on NASDAQ Stock Exchange Capital Market

16 Aug 2019
Change (% chg)

$0.01 (+0.20%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Cooper, Laurence 

Dr. Laurence James Neil Cooper, M.D., Ph.D., is Chief Executive Officer, Director of the Company. Prior to joining us, Dr. Cooper led the Pediatric Cell Therapy service (formally named the BMT program) as a tenured professor at the University of Texas M.D. Anderson Cancer Center, or MD Anderson, where he had worked since 2006. In addition to caring for children, adolescents and young adults undergoing autologous and allogeneic hematopoietic stem-cell transplantation, referred to as HSCT, at MD Anderson, he ran a laboratory translating immunology into clinical practice. His program had multiple investigator-initiated trials that infuse T cells and NK cells to target malignancies. Dr. Cooper also holds an appointment as a Visiting Scientist at MD Anderson and as Adjunct Professor of Pathology & Laboratory Medicine at the Perelman School of Medicine at the University of Pennsylvania. Dr. Cooper obtained his BA at Kenyon College in Gambier, Ohio and M.D. and Ph.D. degrees at Case Western Reserve University in Cleveland before training in Pediatric Oncology and Bone Marrow Transplantation, or BMT, at the Fred Hutchinson cancer Research Center in Seattle.

Basic Compensation

Total Annual Compensation, USD 1,500,000
Restricted Stock Awards, USD --
Long-Term Incentive Plans, USD --
All Other, USD 89,239
Fiscal Year Total, USD 1,589,240

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --